Based at BioArk TechPark in Monthey and supported by the incubation program of the Foundation The Ark, Bioscibex has been selected among the 60 semi-finalists of the 2026 venture competition.
Organized annually, venture is one of Switzerland’s largest startup competitions, attracting several hundred applications each year across multiple sectors. The selection of Bioscibex marks the first stage of a multi-step evaluation process. Bioscibex will now enter the mentoring and coaching phase, where semi-finalists refine their strategy and presentation with the support of experts, ahead of the next jury round.
Advancing innovation in bioproduction
Bioscibex is developing a machine designed to improve the production of monoclonal antibodies. The technology aims to make manufacturing processes faster, more cost-effective, and safer compared to existing methods.
Monoclonal antibodies play a central role in many therapeutic areas, including oncology and autoimmune diseases. Innovations in their production are therefore a key topic within the biopharmaceutical industry.
A recognition within the Swiss startup ecosystem
Being selected as a semi-finalist reflects both the quality of the project and its potential relevance for the life sciences sector.
The upcoming stages of the competition will further assess projects through expert evaluation and pitching sessions, leading to the final selection of winners in June.
More information: Bioscibex
